MedGenome

Servier India, a subsidiary of the French pharma company Servier Group has announced the launch of a patient-centric biomarker…

Could you walk us through the journey of developing the CNS Tumor Methylation Classifier? What were the biggest scientific and…

The CNS Tumour Methylation Classifier can categorise brain tumours into subtypes, offering more accurate and personalised…

MedGenome's campaign, #CarefortheRare aims to bring attention to the challenges faced by families living with rare diseases, while…

The introduction of a new Fund of Funds with ₹10,000 crore and enhanced credit guarantees was a welcomed move

Focus on funding, workforce development, tax reforms, and digital innovation in healthcare

Dr N Soumittra, Disease Head, Ophthalmology, MedGenome, highlights how genetics and environmental factors come together to shape…

The HOPE for Rare Diseases program, established in August 2024 aims to provide whole exome sequencing for impoverished rare…

The partnership aims at an access intervention pilot for offering Whole Genome Sequencing (WGS) testing free of cost to pre…

Launches KaryoSeq to detect genome abnormalities in Prenatal and newborn conditions